Popular Pre-Market Trades in US Stocks

DNA X, up 9.82% in pre-market, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Adobe is up 3.12% in pre-market. Based on recent news,

1. On April 21, Adobe announced it would repurchase up to $25 billion in stock over the next four years. This move demonstrates the company's confidence in its strong cash flow and aims to create long-term value for investors. Following this news, Adobe's stock price rose about 2% in after-hours trading.

2. On April 20, Adobe launched a suite of artificial intelligence tools called CX Enterprise, aimed at helping enterprise customers automate and personalize digital marketing functions. The product launch led to a 2.2% increase in Adobe's stock price during early trading.

3. On April 20, Adobe announced collaborations with several tech companies, including Amazon, Microsoft, Anthropic, OpenAI, and NVIDIA, to ensure its new AI systems can operate across different platforms. This move further boosted market confidence in Adobe's future development, driving the stock price up. Adobe's stock price has fallen about 30% year-to-date.

Top Gainers in Pre-Market US Stocks

Axe Compute is up 154.35% in pre-market. Based on recent news,

1. On April 21, Axe Compute's co-CFO Jeremy Reese Yaukey-Witter reported 1,138 shares of common stock in an initial Form 3 filing submitted on April 16. This news indicates confidence from the company's internal executives in its stock, leading to a significant price increase.

2. On April 20, AlphaTON Capital announced it would be renamed Alpha Compute to reflect its growing AI computing business. This move indicates the company's strategic expansion in the AI field, enhancing market expectations for its future development and further boosting the stock price.

3. On April 20, Alpha Compute appointed Tom Richer as a member of its advisory board to accelerate the implementation of its AI GPU computing infrastructure and confidential cloud strategy. This appointment is interpreted by the market as a significant technological and strategic advancement for the company, further boosting investor confidence. The AI computing industry has performed strongly recently, attracting high investor attention.

Inhibrx is up 30.83% in pre-market, based on recent key news:

1. On April 22, Inhibrx's anti-cancer drug INBRX-106 attracted attention from several pharmaceutical companies, including Merck. The drug, used in combination with Keytruda, showed early trial data indicating a response rate of about 45%, driving the stock price up. Source: Reuters

2. On April 21, Inhibrx released the latest interim data from its clinical-stage biopharmaceutical projects, showing significant progress. This news has boosted market confidence in the company's future development. Source: Reuters

3. On April 20, Inhibrx announced plans to hold a live webcast on April 21 to provide clinical updates on its drug Ozekibart, further attracting investor attention. Source: Reuters The biopharmaceutical industry has been active recently, with high investor interest.

Huachen AI Parking Management Tech, pre-market up 28.13%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation